Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

BACKGROUND: Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Metzinger, Mark P., Saldanha, Suzanne, Gulati, Jaskeerat, Patel, Kershaw V., El‐Ghazali, Ayea, Deodhar, Sneha, Joshi, Parag H., Ayers, Colby, Rohatgi, Anand
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955402/
https://ncbi.nlm.nih.gov/pubmed/33263263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.018136
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados